317 related articles for article (PubMed ID: 30594678)
41. Hydroxamates of para-aminobenzoic acid as selective inhibitors of HDAC8.
Kulandaivelu U; Chilakamari LM; Jadav SS; Rao TR; Jayaveera KN; Shireesha B; Hauser AT; Senger J; Marek M; Romier C; Jung M; Jayaprakash V
Bioorg Chem; 2014 Dec; 57():116-120. PubMed ID: 25462986
[TBL] [Abstract][Full Text] [Related]
42. Are inhibitors of histone deacetylase 8 (HDAC8) effective in hematological cancers especially acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL)?
Amin SA; Khatun S; Gayen S; Das S; Jha T
Eur J Med Chem; 2023 Oct; 258():115594. PubMed ID: 37429084
[TBL] [Abstract][Full Text] [Related]
43. Docking of hydroxamic acids into HDAC1 and HDAC8: a rationalization of activity trends and selectivities.
Ortore G; Di Colo F; Martinelli A
J Chem Inf Model; 2009 Dec; 49(12):2774-85. PubMed ID: 19947584
[TBL] [Abstract][Full Text] [Related]
44. Isophthalic Acid-Based HDAC Inhibitors as Potent Inhibitors of HDAC8 from Schistosoma mansoni.
Stenzel K; Chakrabarti A; Melesina J; Hansen FK; Lancelot J; Herkenhöhner S; Lungerich B; Marek M; Romier C; Pierce RJ; Sippl W; Jung M; Kurz T
Arch Pharm (Weinheim); 2017 Aug; 350(8):. PubMed ID: 28639720
[TBL] [Abstract][Full Text] [Related]
45. Synthesis and applications of benzohydroxamic acid-based histone deacetylase inhibitors.
De Vreese R; D'hooghe M
Eur J Med Chem; 2017 Jul; 135():174-195. PubMed ID: 28453994
[TBL] [Abstract][Full Text] [Related]
46. Rational design of selective HDAC2 inhibitors for liver cancer treatment: computational insights into the selectivity mechanism through molecular dynamics simulations and QM/MM calculations.
Yang Y; Hu B; Yang Y; Gong K; Wang H; Guo Q; Tang X; Li Y; Wang J
Phys Chem Chem Phys; 2021 Aug; 23(32):17576-17590. PubMed ID: 34369509
[TBL] [Abstract][Full Text] [Related]
47. Overexpressed HDAC8 in cervical cancer cells shows functional redundancy of tubulin deacetylation with HDAC6.
Vanaja GR; Ramulu HG; Kalle AM
Cell Commun Signal; 2018 May; 16(1):20. PubMed ID: 29716651
[TBL] [Abstract][Full Text] [Related]
48. Design, Synthesis and Biological Characterization of Histone Deacetylase 8 (HDAC8) Proteolysis Targeting Chimeras (PROTACs) with Anti-Neuroblastoma Activity.
Darwish S; Ghazy E; Heimburg T; Herp D; Zeyen P; Salem-Altintas R; Ridinger J; Robaa D; Schmidtkunz K; Erdmann F; Schmidt M; Romier C; Jung M; Oehme I; Sippl W
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35886887
[TBL] [Abstract][Full Text] [Related]
49. Docking and QSAR Studies of Aryl-valproic Acid Derivatives to Identify Antiproliferative Agents Targeting the HDAC8.
Martínez-Pacheco H; Ramírez-Galicia G; Vergara-Arias M; Gertsch J; Fragoso-Vazquez JM; Mendez-Luna D; Abujamra AL; Cristina CL; Cecilia RM; Mendoza-Lujambio I; Correa-Basurto J
Anticancer Agents Med Chem; 2017; 17(7):927-940. PubMed ID: 27774878
[TBL] [Abstract][Full Text] [Related]
50. Design, synthesis and biological evaluation of tyrosine-based hydroxamic acid analogs as novel histone deacetylases (HDACs) inhibitors.
Zhang Y; Feng J; Liu C; Fang H; Xu W
Bioorg Med Chem; 2011 Aug; 19(15):4437-44. PubMed ID: 21733698
[TBL] [Abstract][Full Text] [Related]
51. Identification of novel isoform-selective inhibitors within class I histone deacetylases.
Hu E; Dul E; Sung CM; Chen Z; Kirkpatrick R; Zhang GF; Johanson K; Liu R; Lago A; Hofmann G; Macarron R; de los Frailes M; Perez P; Krawiec J; Winkler J; Jaye M
J Pharmacol Exp Ther; 2003 Nov; 307(2):720-8. PubMed ID: 12975486
[TBL] [Abstract][Full Text] [Related]
52. Chemical origins of isoform selectivity in histone deacetylase inhibitors.
Butler KV; Kozikowski AP
Curr Pharm Des; 2008; 14(6):505-28. PubMed ID: 18336297
[TBL] [Abstract][Full Text] [Related]
53. Structural origin of selectivity in class II-selective histone deacetylase inhibitors.
Estiu G; Greenberg E; Harrison CB; Kwiatkowski NP; Mazitschek R; Bradner JE; Wiest O
J Med Chem; 2008 May; 51(10):2898-906. PubMed ID: 18412327
[TBL] [Abstract][Full Text] [Related]
54. The clinical significance of histone deacetylase-8 in human breast cancer.
Rahmani G; Sameri S; Abbasi N; Abdi M; Najafi R
Pathol Res Pract; 2021 Apr; 220():153396. PubMed ID: 33691240
[TBL] [Abstract][Full Text] [Related]
55. Azetidinones as zinc-binding groups to design selective HDAC8 inhibitors.
Galletti P; Quintavalla A; Ventrici C; Giannini G; Cabri W; Penco S; Gallo G; Vincenti S; Giacomini D
ChemMedChem; 2009 Dec; 4(12):1991-2001. PubMed ID: 19821480
[TBL] [Abstract][Full Text] [Related]
56. HDAC8, A Potential Therapeutic Target for the Treatment of Malignant Peripheral Nerve Sheath Tumors (MPNST).
Lopez G; Bill KL; Bid HK; Braggio D; Constantino D; Prudner B; Zewdu A; Batte K; Lev D; Pollock RE
PLoS One; 2015; 10(7):e0133302. PubMed ID: 26200462
[TBL] [Abstract][Full Text] [Related]
57. Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs).
Luo Y; Li H
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33266366
[TBL] [Abstract][Full Text] [Related]
58. Non-epigenetic function of HDAC8 in regulating breast cancer stem cells by maintaining Notch1 protein stability.
Chao MW; Chu PC; Chuang HC; Shen FH; Chou CC; Hsu EC; Himmel LE; Huang HL; Tu HJ; Kulp SK; Teng CM; Chen CS
Oncotarget; 2016 Jan; 7(2):1796-807. PubMed ID: 26625202
[TBL] [Abstract][Full Text] [Related]
59. Developing selective histone deacetylases (HDACs) inhibitors through ebselen and analogs.
Wang Y; Wallach J; Duane S; Wang Y; Wu J; Wang J; Adejare A; Ma H
Drug Des Devel Ther; 2017; 11():1369-1382. PubMed ID: 28496307
[TBL] [Abstract][Full Text] [Related]
60. Inhibition and mechanism of HDAC8 revisited.
Chen K; Zhang X; Wu YD; Wiest O
J Am Chem Soc; 2014 Aug; 136(33):11636-43. PubMed ID: 25060069
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
